SALA DE PRENSA DE RENOWN

Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.”   The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. Acerca de Helix Helix es la compañía líder en genómica y vigilancia viral de la población cuyas operaciones se basan en el cuidado clínico, la investigación y el análisis de datos. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.

Leer más About Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results

Brings a new level of convenience, access and affordability to surgical care in northern Nevada. In a collaboration designed to offer consumers additional convenient and affordable options for outpatient surgery, Surgery Center of Reno (SCOR) and Renown Health today announced a new partnership. “We are thrilled to bring a new level of convenience in surgical care to patients and providers in the Reno community and outlying areas, to deliver superior clinical quality and service, and make health care more affordable,” said James Lynch, MD, President, and Chairman of the Board of Directors for the Surgery Center of Reno.  “We trust and value the Surgery Center of Reno and its team of surgeons, clinicians and administrators and the excellent quality of care and compassion they provide to their patients,” said Tony Slonim, MD, DrPH, Renown’s President & CEO. “Given our mutual interests in advancing high-quality and high-value care, this partnership expands capabilities, enhances access and affordability for patients and physicians, improves the health of our community and establishes Renown and the Surgery Center of Reno as the premier destination for surgery in northern Nevada.” This joint venture for outpatient surgery care is the result of the unique collaborative relationship between Renown Health, Reno’s only not-for-profit health care system; and the Surgery Center of Reno, an independent physician owned ambulatory surgery center with Regent Surgical Health as the managing partner. The SCOR and Renown partnership brings together three key elements to serve patients and our community with enhanced outpatient surgery care that includes: Out-of-pocket cost savings for patients. Ambulatory Surgical Centers (ASCs) like Surgery Center of Reno, offer a high-quality, low-cost alternative for many surgical procedures. Patient preference and the desire to decrease healthcare costs continue to fuel Renown’s interest in transitioning appropriate surgeries from hospitals to freestanding ambulatory surgery centers. Significant innovations in minimally-invasive surgical procedures along with advances in anesthesia techniques, reduced complications and recovery times for selected procedures, have helped to make ambulatory surgery centers popular. Renown is focused on creating options for high quality, affordable care for patients and insurance providers by having selected surgical procedures occur in the ASC setting. Comfort and convenience for patients. Surgery Center of Reno offers an upscale experience and has some of the most advanced technology for Ambulatory Surgical Centers in the state. Since all surgeries at SCOR are pre-scheduled, a patient’s procedure is never bumped or delayed by an emergency or trauma case. Surgery is scheduled at ideal times for the patient and family. After surgery, the patient has time to wake up in the recovery room, and then recuperate in their own home.  The same high-quality physicians who work in the operating rooms at Renown hospitals also work as part of the Surgery Center of Reno, including surgeons specializing in Spine, Orthopedics, General Surgery, Ear, Nose & Throat, Pain management, Urology/Lithotripsy, Gynecology, Ophthalmology; Dental/ Oral Surgery, Podiatry and Weight Loss Surgery.   Since their inception more than forty years ago, Ambulatory Surgical Centers have demonstrated an ability to deliver quality and customer service while simultaneously reducing costs. The Surgery Center of Reno and all Ambulatory Surgical Centers are highly regulated, adhere to stringent quality and safety guidelines, are certified by Medicare and the Nevada State Department of Health, accredited with accrediting agencies such as the Accreditation Association for Ambulatory Health Care or The Joint Commission, and have adopted extensive patient safety procedures. Of course, if complications or an emergency were to develop, patients have immediate access to Renown’s hospitals.  “Renown has used our experience through COVID-19 to emerge better and stronger, and we are realigning to meet new consumer demands for health and healthcare services that are convenient, accessible and affordable,” said Bethany Sexton, Chief Transformation Officer. “We are excited to partner with SCOR to exceed people’s expectations and to delight our community with smart, innovative approaches to care. As our nation struggles with how to improve a troubled health care system, the experience of ASCs is a great example of a successful transformation in health care delivery.”  Each year, millions of procedures are performed in outpatient centers. El Surgery Center of Reno funciona desde hace 14 años, y tiene una excelente trayectoria y reputación en nuestra comunidad. Según un informe de julio de 2017 de los Centros de Servicios de Medicare y Medicaid (CMS), aproximadamente el 70 % de todas las cirugías en los EE. UU. se realizan en un entorno ambulatorio. Outpatient and ambulatory surgery centers can save money and improve the efficiency and convenience of care for patients and health care providers alike. ASCs are at the center of today’s most pressing healthcare initiatives- value based care and risk-sharing models. Nic Towle, RN, Administrator at SCOR says, “We are dedicated to providing excellent care in a safe environment and want all of our patients and their families to be comfortable and receive the highest quality surgical care. Not all procedures can take place in an outpatient setting and may require a hospital stay regardless of your preference. We suggest you speak with your doctor to ensure you qualify as a candidate, to learn about all the options and what is best for you.” About SCOR SCOR is a well-established, Medicare certified, AAAHC accredited, multidisciplinary ambulatory surgery center in Reno. The ASC is partnered with a leader in development and management of ASCs, Regent Surgical Health based in Westchester, Illinois. Desde 2006, SCOR es un proveedor integral en el mercado que ofrece servicios ambulatorios al norte de Nevada y al noreste de California. SCOR has proven to be a leader in expanding services that include minimally invasive techniques in spine and general surgery. The surgery center has one of the strongest group of fellowship-trained and board-certified specialists and has won multiple awards for clinical excellence. About Renown Health Renown Health is the region’s largest, locally owned and governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Con una fuerza laboral diversa de más de 7,000 empleados, Renown ha fomentado una cultura de excelencia, determinación e innovación de larga data. La organización se compone de un centro de urgencias, dos hospitales de cuidados agudos, un hospital infantil, un hospital de rehabilitación, un grupo médico y una red de atención de urgencias y Hometown Health, la compañía de seguros sin fines de lucro más grande de la región y de propiedad local, Hometown Health. Renown’s institute model addresses social determinants of health and includes: Child Health, Behavioral Health & Addiction, Healthy Aging and Health Innovation. Clinical institutes include: Cancer, Heart and Vascular Heath, Neurosciences and Robotic Surgery. Actualmente, Renown está inscribiendo participantes en el estudio genético de salud poblacional basado en la comunidad más grande del mundo, el Healthy Nevada Project®. Visite renown.org para obtener más información.

Leer más About Surgery Center of Reno To Offer Option for Outpatient Surgery

El enfoque basado en la comunidad del Healthy Nevada Project revela que hasta un 90 % de los riesgos de padecer afecciones genéticas de Nivel 1 de los CDC no se detecta cuando se usan pautas de atención clínica. In a new study published today in the journal Nature Medicine, researchers behind the Healthy Nevada Project® suggest that community-based genetic screening has the potential to efficiently identify individuals who may be at increased risk for three common inherited genetic conditions known to cause several forms of cancer and increased risk for heart disease or stroke. En 2018, el Healthy Nevada Project® (el mayor estudio de salud poblacional basado en la comunidad que combina datos genéticos, clínicos, ambientales y sociales) comenzó a notificarles a los participantes del estudio que habían dado su consentimiento sobre ciertas variantes genéticas que los predisponían a padecer las afecciones genéticas de Nivel 1 de los Centros para el Control y la Prevención de Enfermedades (Centers for Disease Control and Prevention, CDC). The study focused on identifying carriers of these conditions, which include Hereditary Breast and Ovarian Cancer, Lynch Syndrome, and Familial Hypercholesterolemia, because they are the most common conditions and early detection and treatment could significantly lower morbidity and mortality. Los resultados iniciales de casi 27,000 participantes del estudio mostraron que el 90 % de los portadores de las afecciones genéticas de Nivel 1 de los CDC no había sido previamente identificado en un entorno clínico. The authors conclude that population genetic screening would identify at-risk carriers not identified during routine care. “Our first goal was to deliver actionable health data back to the participants of the study and understand whether or not broad population screening of CDC Tier 1 genomic conditions was a practical tool to identify at-risk individuals,” explained Joseph Grzymski, Ph.D., the principal investigator of the Healthy Nevada Project®, a research professor at the Desert Research Institute (DRI), chief scientific officer for Renown Health and lead author of the study. “Now, two years into doing that, it is clear that the clinical guidelines for detecting risk in individuals are too narrow and miss too many at risk individuals.” Del grupo de 26,906 participantes del Healthy Nevada Project® que el equipo de investigación de Grzymski estudió, 358 (el 1.33 %) eran portadores de afecciones de Nivel 1 de los CDC. Sin embargo, solo el 25 % de esas personas cumplían las pautas clínicas para realizarse exámenes de detección genética. Además, más del 20 % de los portadores ya tenía un diagnóstico de enfermedad relacionada con la afección genética subyacente. “We’re at a point now where it’s possible to do clinical-grade genetic screening at population-scale,” added James Lu, M.D. Ph.D., co-founder and chief scientific officer of Helix and senior co-author of the study. “What this study demonstrates is the potential impact of doing so. By making genetic screening available more broadly, we can help the millions of Americans who are unaware that they are living at increased risk for highly actionable, genetic conditions take action.” En particular, el estudio descubrió que de los 273 participantes que eran portadores de las afecciones genéticas de Nivel 1 de los CDC y que tenían información de registros clínicos, solo 22 personas mostraron sospechas previas de tener estas afecciones genéticas subyacentes. “For the first time, we are providing information at the individual level so study participants can make lifesaving changes to reduce their risk based on their genetics,” said Anthony Slonim, M.D., Dr.PH., FACHE, president and CEO of Renown Health and co-director of the Project® study. “We’re conducting research on the community level to develop leading-edge research on health determinants for entire neighborhoods, states and eventually, the country. Returning these results allows us to understand the prevalence of genetically programmed diseases and illnesses that we have here in Nevada and ensure we are providing the best prevention and care plans. For the individual, the return of results can be life changing.” According to the CDC, early detection and intervention of the Tier 1 genetic conditions could have a meaningful potential for clinical action ability and a positive impact on public health. El Healthy Nevada Project®, que se lanzó en 2016, ofrece pruebas genéticas gratuitas a todos los residentes de Nevada, mayores de 18 años, interesados en obtener más información sobre su salud y perfil genético. Con más de 50,000 participantes del estudio inscritos en cuatro años, el Healthy Nevada Project® se ha convertido en el estudio genético de más rápida inscripción del mundo. For more about the Healthy Nevada Project® please visit healthynv.org     Renown Institute for Health Innovation is a collaboration between Renown Health – a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute – a recognized world leader in investigating the effects of natural and human induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at Healthynv.org. Helix is the leading population genomics company operating at the intersection of clinical care, research, and genomics. Its end-to-end platform enables health systems, life sciences companies, and payers to advance genomic research and accelerate the integration of genomic data into clinical care. Powered by one of the world's largest CLIA / CAP next-generation sequencing labs and its proprietary Exome+Ⓡ assay, Helix supports all aspects of population genomics including recruitment and engagement, clinically actionable disease screening, return of results, and basic and translational research. In response to the COVID-19 public health crisis, Helix has launched a sensitive and scalable end-to-end COVID-19 test system to meet the needs of health systems, employers, governments, and other organizations across the country. Obtenga más información en www.helix.com.

Leer más About Los exámenes de detección genética poblacionales demuestran que identifican de manera eficiente un aumento en el riesgo de padecer enfermedades hereditarias

Presented by the Desert Research Institute and Renown Health, DANA will help people learn more about the Healthy Nevada Project® and their own unique, genetic health traits What is the Healthy Nevada Project®? What are the benefits of joining this research study? How can I find out if I carry genes for health risks like heart disease, hereditary breast and ovarian cancer syndrome and Lynch syndrome? What if a holographic avatar, powered by artificial intelligence (AI), could answer all these questions and more? DANA has all the answers, she is a virtual assistant with “DNA” in her name, presented by the Renown Institute for Health Innovation (Renown IHI), a collaboration between Renown Health and the Desert Research Institute (DRI). This life-sized, holographic avatar will greet individuals outside Renown Regional Medical Center’s Sierra Café, and talk to them about the Healthy Nevada Project, the world’s largest community-based genetic population health study. Los representantes de medios de comunicación están invitados a reunirse con DANA esta mañana, desde las 10 a.m. hasta el mediodía. Responda a este correo electrónico o llame al (775) 691-7308 para coordinar una reunión. “Unfortunately, Nevada ranks among the lowest in the nation for health outcomes—and we are working to change that,” said Anthony Slonim, M.D., D.Ph., president and CEO of Renown Health and president of Renown Institute for Health Innovation. “Through the Healthy Nevada Project® , our goal is to offer genetic testing to every Nevadan interested in learning more about their health and genetic profile. Thanks to this advanced technology, DANA will offer people a personalized explanation of the Project, and help them take the next step to better understand their health, and their health risks, so they can modify their behavior and ultimately, live a healthier, happier life.” Con más de 51,000 participantes del estudio inscritos hasta la fecha, el Healthy Nevada Project® se considera el estudio genético de más rápida inscripción del país. The Project is also the first of its kind to return clinical results to study volunteers, which means participants can learn their genetic risks tied to heart disease and certain cancers, as well as lifestyle changes that could potentially help reduce their risk and prevent disease. Furthermore, participants can choose to share their information with their medical provider to improve and enhance their medical care. “We are always happy to engage with our study participants and look forward to having them meet and engage with DANA,” said Joseph Grzymski, Ph.D., research professor at DRI, principal investigator of the Healthy Nevada Project® and chief scientific officer for Renown Health. “At a time of physical distancing and limiting human contact where possible, using tools like an avatar and AI are important for communicating, whether it be for genetics, vaccinations or other important health information.” Visitors can interact with DANA through a touch screen (cleaned and sanitized after every encounter) to learn more about the study, enter their contact information and schedule an appointment to join the free genetics study or receive more information about their test results. Kiosk visitors are asked to maintain physical distance guidelines and use the hand sanitizer and Sani Wipes available next to the kiosk.     Renown Institute for Health Innovation is a collaboration between Renown Health - a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California; and the Desert Research Institute - a recognized world leader in investigating the effects of natural and human-induced environmental change and advancing technologies aimed at assessing a changing planet. Renown IHI research teams are focused on integrating personal healthcare and environmental data with socioeconomic determinants to help Nevada address some of its most complex environmental health problems; while simultaneously expanding the state’s access to leading-edge clinical trials and fostering new connections with biotechnology and pharmaceutical companies. Learn more at healthynv.org.

Leer más About Presentación de Dana, el nuevo quiosco holográfico tamaño real del Renown Institute for Health Innovations

Hoy, según las recomendaciones del cirujano general de los EE. UU. y del American College of Surgeons, el Comité Ejecutivo Médico Conjunto de Renown Health decidió que, a partir del martes, 17 de marzo, los casos quirúrgicos programados en el Renown Regional Medical Center y en el Renown South Meadows Medical Center, que se consideren ELECTIVOS OPCIONALES se pospondrán a una fecha posterior. Los pacientes que tienen programadas cirugías ELECTIVAS OPCIONALES recibirán una llamada telefónica de representantes de Renown Health la próxima semana. Surgeon’s offices will also be reaching out to assist patients with rescheduling their surgeries for a future date.  Elective surgeries that are REQUIRED and not optional will be evaluated on a case-by-case basis daily with the surgeon, patient and a medical leadership review committee at Renown. Your surgeon’s office will be in contact with you with more information about these REQUIRED surgeries This temporary measure will allow Renown’s physicians and staff to enact the emergency preparedness plans they have been developing for weeks to create additional capacity for inpatients and to continue to deliver high quality care during the anticipated surge in COVID-19 cases in northern Nevada. The new guidelines do NOT apply to EMERGENCY surgeries performed in Renown hospitals. There are different types of surgery, this decision impacts Elective-Optional surgeries only. Elective – Optional surgery – Elective surgeries are not usually necessary for the individual to stay in good health. They are non-emergency and planned in advance. A wide range of surgeries can be elective. Most cosmetic surgeries are elective. Other surgeries such as organ donation, scoliosis surgery, tonsillectomies and other minor surgeries can also be considered elective. Required surgery – Surgery which needs to be done in order to retain quality of life. As opposed to urgent or emergency surgery, required surgeries do not need to be performed immediately. Examples of required surgery are kidney stone or tumor removal. Urgent or emergency surgery – When a patient’s condition is life threatening, surgery is considered emergent. Emergency surgeries must be performed immediately, even when the patient is unconscious and cannot give consent. Examples include trauma and appendicitis. Life-threatening conditions can occur during labor and delivery which may require emergency surgery. Other services making changes include: Pulmonary Services and Procedures Renown Health today will begin rescheduling patients scheduled for Pulmonary Function Testing, Outpatient bronchoscopy and patients at Thomas S. Dolan Pulmonary Rehabilitation. Renown llamará a los pacientes afectados por este cambio para reprogramar sus citas para el lunes 20 de abril de 2020 o en una fecha posterior. Starbucks at Renown and Renown Dining Options As with many of the Starbucks around the U.S., the Starbucks at Renown Regional Medical Center will shift to a “to-go” model, with no seating available. The cafeterias at Renown Regional Medical Center and South Meadows Medical Center remain open, will temporarily eliminate self-service options and will add more ‘grab and go’ options. Other Renown Services Remain Open Renown Medical Group offices remain open. Planned imaging procedures such as ultrasound, computed tomography (CT), magnetic resonance imaging (MRIs), mammograms and non-invasive cardiology testing will continue at Renown hospitals and office locations and will NOT be postponed at this time. Patients confirmed for imaging appointments will be contacted prior to their scheduled visits to identify those who may be at higher risk of COVID-19 infection. Renown has expanded access to Teladoc virtual visits, available to all Hometown Health and Senior Care Plus subscribers. Para obtener información actualizada sobre el abordaje de Renown para mantener la seguridad de la comunidad, visite nuestro sitio web en https://www.renown.org/covid-19/.     About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. Renown es uno de los mayores empleadores privados de la región y cuenta con una fuerza laboral de más de 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown has a long tradition and commitment to continually improve the care and the health of our community. Visite renown.org para obtener más información.

Leer más About Update on Elective Surgical Procedures and Medical Services

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. En virtud de los términos del acuerdo de colaboración y licencia, Gilead proporcionará fondos al Renown IHI para secuenciar y analizar el ADN de 15,000 personas que viven con EHNA o con enfermedad de hígado graso no alcohólico (EHGNA), así como de una cohorte de control de 40,000 personas en el estado de Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health es la red de atención médica más completa e integrada de Nevada y mantiene registros médicos electrónicos para 1.02 millones de pacientes registrados. En 2016, Renown Health y el Desert Research Institute crearon el Healthy Nevada Project (HNP), el primer estudio de salud poblacional basado en la comunidad del país. En 2017, el HNP comenzó una sociedad con Helix para aprovechar sus servicios de salud poblacional, la secuenciación Exome+™ y las herramientas de participación del consumidor. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. El HNP actualmente tiene 40,000 participantes. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.”     About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. La EHNA es más frecuente en personas con ciertas afecciones, que incluyen obesidad y diabetes tipo 2. There are currently limited approved treatments for patients living with NASH.   About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead opera en más de 35 países alrededor del mundo, con sede central en Foster City, California. Para obtener más información sobre Gilead Sciences, visite el sitio web de la empresa en www.gilead.com.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown es uno de los mayores empleadores privados de la región y cuenta con una fuerza laboral de más de 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org.    About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Mediante el uso de su ensayo Exome+™ de propiedad exclusiva, un exoma de tipo panel mejorado con más de 300,000 regiones no codificantes informativas, Helix ofrece a los sistemas de salud una solución escalable que permite el descubrimiento de información genética médicamente relevante y que potencialmente puede salvar vidas. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Obtenga más información en www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.   Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Estos y otros riesgos se describen en detalle en el Informe Trimestral de Gilead en el Formulario 10-Q para el trimestre que finalizó el 31 de marzo de 2019, presentado ante la Comisión de Bolsa y Valores de los EE. UU. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.   Additional Media Contact: Sung Lee, Investors                                                                                                                                                        650-524-7792 Arran Attridge, Media                                                                                                                                                        650-425-8975

Leer más About Gilead Sciences y el Renown Institute for Health Innovation anuncian una colaboración estratégica para promover la comprensión de la esteatohepatitis no alcohólica (EHNA)

Two Open-Heart Surgeons and Two Advanced Practitioners Bring Nearly 70 Years of Local Experience. As part of a continuing focus on offering comprehensive care for patients experiencing cardiac and vascular disease across northern Nevada, Renown Health Department of Surgery and Renown Institute for Heart & Vascular Health have developed Renown’s first division of cardiothoracic surgery dedicated to heart surgery patients. “Hoy me enorgullece anunciar que los cirujanos cardiotorácicos, Athan Roumanas, M.D., FACS, y Joseph Brandl, M.D., FACS, que representan más de 45 años de experiencia combinada en el cuidado de residentes de Nevada con necesidad de una cirugía a corazón abierto, dirigirán este nuevo consultorio en Renown”, dijo Anthony Slonim, M.D., Dr.PH., FACHE, presidente y director ejecutivo de Renown Health. “Las profesionales de atención avanzada Cindy Powers y Ashley White aportan otros 23 años de atención experta a nuestra comunidad y a la nueva división de cirugía cardiotorácica”. El Dr. Roumanas tiene 18 años de experiencia en el norte de Nevada. He is a clinical associate professor of surgery at the University of Nevada, Reno School of Medicine (UNR Med) and currently serves as medical director of cardiothoracic surgery for Renown Regional Medical Center. Desde 1991, el Dr. Brandl ha cuidado de nuestra región y ha ocupado numerosos puestos en toda la comunidad, incluido el de director de Cirugía Cardíaca de Renown y profesor adjunto de la comunidad en la UNR Med. Renown Institute for Heart & Vascular Health offers the most highly-skilled and experienced heart and vascular team and the most advanced heart center in the region. Renown has long been the region’s heart care leader – performing the area’s first open-heart surgery, angioplasty, stent and valve replacements decades ago. En 2015, Renown Regional se convirtió en el primer hospital de la región en ofrecer reemplazo de válvula aórtica transcatéter (transcatheter aortic valve replacement, TAVR), una alternativa salvadora a la cirugía a corazón abierto para pacientes considerados de alto riesgo o inoperables. Renown se encuentra entre los hospitales de mejor desempeño del país para el tratamiento de ataques cardíacos y es uno de los únicos 105 hospitales de todo el país en recibir el premio ACTION Registry Silver Performance Achievement Award del Colegio Estadounidense de Cardiología, que reconoce el éxito en la implementación de un estándar de atención más alto para pacientes con ataques cardíacos. Additionally, Renown’s Roseview, Sierra and Cardiac Intensive Care Units (ICUs) were the only ICUs in Nevada to receive the Beacon Award of Excellence from the American Association of Critical Care Nurses. This distinction is based on sustained unit performance and patient outcomes that exceed national benchmarks. As Reno’s only locally-owned, charitable, not-for-profit integrated health network, Renown continues to meet customer demand for affordable healthcare and enhanced service and access by keeping the highest levels of clinical quality care right here in our community. Los pacientes que necesitan atención cardíaca avanzada pueden hablar con su proveedor de atención médica sobre la atención de especialidad del Renown Medical Group, con el que puede comunicarse llamando al 775-982-6270 o si visita renown.org/HeartCare.

Leer más About Nationally Recognized Heart Surgeons Join Renown Health